06618 Overview

JD Health and Ali Health Performance: Both JD Health and Ali Health reported strong revenue growth last year, with pharmaceutical sales increasing by 20-30%, significantly outpacing the national market growth of only 2%.

Market Share Dynamics: The growth reflects a continuous gain in market share by online platforms over traditional hospital channels, despite a decrease in the number of physical pharmacies.

Broker Ratings and Forecasts: CLSA maintained an Outperform rating for JD Health and raised earnings forecasts, while also increasing target prices for both JD Health and Ali Health, indicating potential upside.

Valuation Insights: HSBC Global Research noted that Ali Health's current valuation has largely accounted for recent AI developments, suggesting limited room for further upside.

Strategic Agreement: iMEDWAY Technology has signed a cooperation agreement with Beijing Jingdong Jiankang, a subsidiary of JD HEALTH, focusing on hospital digital upgrades and intelligent construction.

AI and Supply Chain Integration: The partnership aims to develop a new "AI+Supply Chain" solution that leverages both companies' strengths in medical informatization and pharmaceutical supply chains to innovate medical service models.

Growth Expectations: CLSA anticipates JD HEALTH will sustain growth in the second half of 2025, with a projected 24.5% year-on-year revenue increase to RMB37.1 billion, driven by strong sales during Double 11 and a rise in flu infections in December.

Profit Forecasts: The broker expects adjusted EBIT to potentially double year-on-year to RMB2.1 billion, with a 16% revenue growth forecast for 2026, supported by improved gross margins and operational efficiency.

Revised Profit Estimates: CLSA has raised its adjusted net profit forecasts for JD HEALTH by 1% for FY2026 and 2% for FY2027, reflecting a recovery in drug sales and profit growth potential.

Rating and Target Price: The broker maintains an Outperform rating for JD HEALTH and keeps its target price at $71, indicating confidence in the company's future performance.

JD Health Team Composition: JD Health has established a team of doctors for its Check-Up Center, with all members holding intermediate or higher professional titles, and 22% being chief doctors from key departments.

AI Technology Implementation: The company plans to integrate AI technology into its health check-up services, which is expected to enhance report production efficiency by 135% and reduce the average time for users to receive health reports by 3.5 days.

Market Performance: The HSI fell 0.1% to 26,558, while the HSCEI and HSTECH also experienced declines of 0.3% and 0.4%, respectively, with a total half-day turnover of $131.628 billion.

Chip Stocks Surge: External memory chip stocks saw significant gains, with Disco hitting the day limit and ASMPT rising 6%, while other chip stocks like HUA HONG SEMI and INNOSCIENCE also posted positive performances.

Tech Stock Movements: KINGDEE INT'L surged 3.2% on profit expectations, while BIDU-SW rose 4.2% after positive forecasts from JPMorgan; however, major players like TENCENT and MEITUAN-W saw slight declines.

Economic Indicators: China's unemployment rate remained stable at 5.1%, and the Loan Prime Rate for January 2026 was unchanged at 3.00%, aligning with forecasts.

Collaboration Announcement: JD Health has partnered with Beijing Peak Biology Pharmaceuticals to develop a comprehensive health management solution that encompasses screening, diagnosis, treatment, medication, follow-up, and protection.

Service Enhancement Goals: The collaboration aims to improve health service delivery by integrating digital technology and industrial resources, creating a closed-loop service that spans preventive intervention to rehabilitation management.